| Literature DB >> 34527783 |
Abhishek Shankar1,2, Deepak Saini3, Shubham Roy4, Sachidanand Jee Bharati5, Seema Mishra5, Pritanjali Singh6.
Abstract
Cancer cachexia is an important concern in cancer patients in view of advanced stage at presentation. The treatment goal for cachexia is the reversal of the loss of body weight and muscle mass with a variety of pharmacological agents. Various treatment guidelines focus on patients with advanced cancer who are likely to suffer from refractory cachexia. There is a paucity of data on research directed to cancer cachexia on cancer patients. Complementary and alternative medicines (CAMs) are widely use at some or other point of time by the majority of cancer patients in spite of little or no evidence to support that. There are many CAM which have been tried in different set up for cancer cachexia. These medicines are well accepted in view of lesser side effects and easy to use. There is a need for more randomized controlled trials with larger sample size with longer follow-up to generate more evidence in support to the use of CAM in cancer and cancer cachexia. Copyright:Entities:
Keywords: Complementary and alternative medicine; cancer; cancer cachexia; herbal medicine; weight loss
Year: 2021 PMID: 34527783 PMCID: PMC8420927 DOI: 10.4103/apjon.apjon-2149
Source DB: PubMed Journal: Asia Pac J Oncol Nurs ISSN: 2347-5625
Herbal medicines in cancer cachexia[3536373839404142434445]
| Common name | Major active ingredients | Biological activity | Evidence of anticancer activity |
|---|---|---|---|
| Ginseng | Triterpene glycosides, ginsenosides | Immunemodulation, vasorelaxation, antioxidation, anti-inflammation, and anticancer | Preclinical: Inhibits cancer growth and potentiates |
| Rhubarb | DPPH | Hydroxyl radical scavenging | Preclinical: Extensive cytotoxicity to the cells antioxidant potential exhibited efficiency |
|
| Polysaccharides, saponins, and lavonoids | Immunomodulatory, anticancer, and antiviral | Preclinical: Stimulates the production of IL-6 and TNF and enhances the activity of LAK cells |
| TJ-48 | Includes 10 herbs | Immunomodulatory, anticancer | Preclinical: Inhibits cancer growth by the regulation of estrogen receptors or enhancement of systemic |
| TJ-41 | Includes seven herbs | Immunomodulatory, anticancer | Preclinical: Inhibits cancer growth by inducing apoptosis, arresting the cell cycle, and enhancing immunity |
| PHY906 | Includes four herbs | Immunomodulatory, anticancer | Preclinical: Enhances the antitumor efficacy of some anticancer drugs and alleviates side effects of antitumor therapies, such as diarrhea |
| Rikkunshito | Atractylodis lanceae rhizoma | Though a neural reflex involving presynaptic cholinergic and 5-HT3 receptors | Preclinical: Enhance cytoprotection increases gastrol motility stimulate ghrelin secretion |
DPPH: 2,2-Diphenyl-1- picrylhydrazyl’, IL-6: İnterleukin-6, TNF-α: Tumor necrosis factor-α, LAK: Lymphokine-activated killer, QOL: Quality of life, A. sinensis: Angelica sinensis, P. lactiflora: Paeonia lactiflora, A. macrocephala: Atractylodes macrocephala, P. cocos: Poria cocos, C. cassia: Cinnamomum cassia, A. membranaceus: Astragalus membranaceus, L. wallichii: Ligusticum wallichii, G. inflate: Glycyrrhiza inflate, R. glutinosa: Rehmannia glutinosa, P. tuber: Pinellia tuber, S. baicalensis: Scutellaria baicalensis, Z. fructus: Zizyphi fructus, P. ginseng: Panax ginseng, G. uralensis: Glycyrrhiza uralensis, Z. jujube: Ziziphus jujube